Anti-TNFα agents are the best choice in preventing postoperative Crohn's disease A meta-analysis /
Despite the high rate of postoperative recurrence (POR) in Crohn's disease (CD), there is no widely accepted consensus on its prevention.To compare the efficacy of biological and conventional therapies in preventing POR of CD.We searched four electronic databases up to April 2019 for articles t...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2019
|
| Sorozat: | DIGESTIVE AND LIVER DISEASE
51 No. 8 |
| doi: | 10.1016/j.dld.2019.05.027 |
| mtmt: | 30734484 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/18110 |
| LEADER | 02609nab a2200373 i 4500 | ||
|---|---|---|---|
| 001 | publ18110 | ||
| 005 | 20200130145310.0 | ||
| 008 | 200130s2019 hu o 0|| zxx d | ||
| 022 | |a 1590-8658 | ||
| 024 | 7 | |a 10.1016/j.dld.2019.05.027 |2 doi | |
| 024 | 7 | |a 30734484 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Erős Adrienn | |
| 245 | 1 | 0 | |a Anti-TNFα agents are the best choice in preventing postoperative Crohn's disease |h [elektronikus dokumentum] : |b A meta-analysis / |c Erős Adrienn |
| 260 | |c 2019 | ||
| 300 | |a 1086-1095 | ||
| 490 | 0 | |a DIGESTIVE AND LIVER DISEASE |v 51 No. 8 | |
| 520 | 3 | |a Despite the high rate of postoperative recurrence (POR) in Crohn's disease (CD), there is no widely accepted consensus on its prevention.To compare the efficacy of biological and conventional therapies in preventing POR of CD.We searched four electronic databases up to April 2019 for articles that examined the efficacy of different preventive therapies against POR. Our PICO was: (P) adults with CD who underwent intestinal resection, (I) biological agents, (C) conventional therapies or a placebo, and (O) clinical, endoscopic, and histological POR.Anti-TNFα agents were significantly better in preventing clinical, endoscopic, severe endoscopic and histological POR compared to conventional therapies (OR: 0.508, 95% CI: 0.309-0.834, P = 0.007; OR: 0.312, 95% CI: 0.199-0.380, P < 0.001; OR: 0.195, 95% CI: 0.107-0.356, P < 0.001; and OR: 0.255, 95% CI: 0.106-0.611, P = 0.002, respectively), as well as in the subgroup of nonselected CD patients (OR: 0.324, 95% CI: 0.158-0.664, P = 0.002; OR: 0.225, 95% CI: 0.124-0.409, P < 0.001; and OR: 0.248, 95% CI: 0.070-0.877, P = 0.031, respectively). Infliximab and adalimumab proved to be equally effective in preventing endoscopic POR.Anti-TNFα agents are more effective in preventing clinical, endoscopic and histological POR than conventional therapies, even in nonselected CD patients. | |
| 700 | 0 | 2 | |a Borbásné Farkas Kornélia |e aut |
| 700 | 0 | 2 | |a Hegyi Péter |e aut |
| 700 | 0 | 2 | |a Szabó Anikó Nóra |e aut |
| 700 | 0 | 2 | |a Balaskó Márta |e aut |
| 700 | 0 | 2 | |a Veres Gábor |e aut |
| 700 | 0 | 2 | |a Czakó László |e aut |
| 700 | 0 | 2 | |a Bajor Judit |e aut |
| 700 | 0 | 2 | |a Alizadeh Hussain |e aut |
| 700 | 0 | 2 | |a Rakonczay Zoltán, ifj. |e aut |
| 700 | 0 | 2 | |a Mikó Alexandra |e aut |
| 700 | 0 | 2 | |a Habon Tamás |e aut |
| 700 | 0 | 2 | |a Erőss Bálint Mihály |e aut |
| 700 | 0 | 2 | |a Bérczi Bálint |e aut |
| 700 | 0 | 2 | |a Sarlós Patrícia |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/18110/1/30734484_Eros_DLD-19-148_R2.pdf |z Dokumentum-elérés |